Geninus Australia

About Geninus Australia

Geninus Inc. is a biotechnology firm specializing in genomic and transcriptomic analysis, spun off from the Samsung Genomics Research Institute in 2018. The company, led by CEO Woong Yang Park, focuses on providing clinical genome analysis solutions to inform personalized cancer treatments. Donghyun Park serves as the company's CTO and Research Director.

The core of Geninus's business revolves around its genomic-based disease prevention and analysis platforms. Its main clientele includes major hospitals in Korea and Japan, as well as academic and biotechnology partners. The company generates revenue by providing these advanced genomic analysis services and platforms. Its flagship product, CancerSCAN, is a comprehensive cancer genome diagnostics platform. This platform is utilized to detect genetic mutations through deep sequencing of tumor DNA, helping to identify targeted therapeutics and immunotherapies for cancer patients. CancerSCAN encompasses an information management system, bioinformatics pipeline, variant annotation, and clinical reporting.

In addition to CancerSCAN, Geninus operates Celinus, a single-cell genome analysis platform geared towards biomarker discovery. The company has also developed AI-driven tools, such as MEDINSIGHT for digital pathology, which aims to provide faster and more precise diagnoses. Geninus has actively formed partnerships to enhance its offerings, such as a collaboration with Ocean Genomics to co-develop RNA-based biomarkers and integrate advanced AI-based transcriptome analysis into its CancerSCAN platform. The company has a presence in Australia, where it is listed as a certified service provider.